Real-world experience with abiraterone in metastatic castration-resistant prostate cancer

Aim: To evaluate abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: This is a multicenter retrospective analysis, involving 44 consecutive abiraterone-treated mCRPC patients, in either chemotherapy-naive or postdocetaxel setting. Results: The study cohort's median age was 68.7 (50-88) years, and the median duration of abiraterone treatment was 8 (1-36) months. Of the 44 patients, 23 (52%) and 21 (47%) patients were in chemotherapy- naive and postdocetaxel groups, respectively. Eastern Cooperative Oncology Group performance status score was 0-1 and 2-3 in 65% and 34% of chemotherapy-naive and 85% and 15% of postdocetaxel patients, respectively. Prostate-specific antigen (PSA) response was achieved in 13 (56.5%) chemotherapy-naive and 14 (66.6%) postdocetaxel patients. The median time to PSA progression was 12 (10.5-13.5) months. Objective radiological response was achieved in 11 (34.6%) patients, stable disease in 16 (55.1%) patients, and progressive disease in 3 (6.8%) patients. Median time to radiographic progression was 10.8 (10.3-11.4) months. Median overall survival was not reached (mean = 17 [14-20.5] months). The most common adverse events related to mineralocorticoid excess include hypokalemia (12%), fluid retention/edema (28%), and hypertension (8%). Conclusion: This study supports the safety and efficacy of abiraterone for mCRPC patients in the real-world setting.